Chris Gray


Chris Gray conducts research on an antimicrobial peptide, which is considered a strong candidate for future antibiotic replacement. His work has the potential to affect drug discovery in this area. Past work has already yielded software and tools that he makes freely available to other academics.

This research is focused on studying the antimicrobial activity of the antimicrobial peptide HHC-36, which is highly active against strains of drug-resistant bacteria, while remaining mostly nontoxic to mammalian host cells. Compute Canada infrastructure is used to identify the structure of this peptide, both in bulk water and near model membranes, and its interaction with model membranes. The results of this research have the potential to impact Canadians by providing quantitative predictions and accurate measurements in the strategic field of antimicrobial drug discovery. HHC-36 peptide is already patented by Bob Hancock and coworkers in UBC, and is considered a strong candidate for a future antibiotic replacement. This research would not be possible without Compute Canada infrastructure, as it involves microsecond-long, all-atom simulations of peptide-membrane systems. Our group has already spent more than 1,000 core-years of computation time on various Compute Canada clusters over the past two years, toward completion of this project. We estimate about 2.52 million CPU hours of computation time will be needed for successful completion of this project.